Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

E-Poster Display

551P - Phase I study of lurbinectedin in Japanese patients with pretreated advanced tumours: Final results

Date

17 Sep 2020

Session

E-Poster Display

Topics

Clinical Research

Tumour Site

Presenters

Shunji Takahashi

Citation

Annals of Oncology (2020) 31 (suppl_4): S462-S504. 10.1016/annonc/annonc271

Authors

S. Takahashi1, T. Shimizu2, T. Doi3, J.A. Lopez-Vilarino4, R. Nunez Martin4, C. Kahatt4, C. Fernandez Teruel4, H. Sasamoto5, A. Zeaiter4

Author affiliations

  • 1 Department Of Medical Oncology, The Cancer Institute Hospital of JFCR, 135-8550 - Koto-ku/JP
  • 2 Department Of Experimental Therapeutics, National Cancer Center Hospital, Tokyo/JP
  • 3 Experimental Therapeutics Dept., National Cancer Center Hospital East, 277-8577 - Kashiwa/JP
  • 4 Clinical Oncology, Pharma Mar, S.A., 28770 - Madrid/ES
  • 5 Medical & Scientific Service, IQVIATM, 108-0074 - Tokyo/JP

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 551P

Background

The recommended dose (RD) of lurbinectedin in non-Japanese patients (pts) is 3.2 mg/m2 on Day 1 every three weeks (q3wk). Previous dose escalation in Japanese pts resulted in a maximum tolerated dose (MTD) of 3.2 mg/m2 on Day 1 q3wk. Neutropenia was the main dose-limiting toxicity (DLT). A new dose escalation was done with primary granulocyte colony-stimulating factor (G-CSF) prophylaxis.

Methods

Japanese pts with solid tumours (excluding colorectal cancer or central nervous system primary tumors), adequate organ function and ECOG performance status 0-2 were treated at 2 dose levels (3.2 and 3.5 mg/m2) with primary G-CSF prophylaxis, using a 3+3 escalation design.

Results

Eleven pts (4 female/7 male) were treated and evaluated for safety and efficacy. Median (range) age was 61 (40-77) years, albumin was 4.3 (3.2-5.0) g/dL, and number of previous lines was 3 (1-3) lines. Tumors comprised breast (n=2), biliopancreatic (n=2), small cell lung cancer (n=1), endometrial (n=1) and oropharyngeal (n=1), among others. The two pts treated at 3.5 mg/m2 had DLTs: grade (G) 4 ventricular arrhythmia associated with G4 neutropenia and G4 thrombocytopenia; and delayed G4 transaminase increase in Cycle 2. Two of 9 pts (22.2%) treated at 3.2 mg/m2 had DLTs: G4 thrombocytopenia. 3.2 mg/m2 was defined as the RD with primary G-CSF prophylaxis. Main G3/4 adverse events at the RD were hematological: G3 thrombocytopenia (n=2 pts; 22.2%) and G4 neutropenia (n=1; 11.1%). G3/4 non-hematological toxicities were G3 transaminase increase (n=2; 22.2%) and G3 pulmonary infection (n=1; 11.1%). All pts at the RD had stable disease (SD) as best response, with long-lasting stabilizations (SD>4 months) in 4 pts (44.4%). The pharmacokinetic (PK) profile at the RD was similar to that found in non-Japanese pts, with mean (standard deviation) total body clearance 13.9 (8.2) L/h, half-life 42.5 (12.5) h, and volume of distribution at steady- state 414.9 (196.6) L.

Conclusions

The RD of lurbinectedin given on Day 1 q3wk with primary G-CSF prophylaxis in Japanese pts is 3.2 mg/m2. This RD was associated with mild toxicity. Main DLTs were hematological. Japanese pts showed a similar PK profile compared to non-Japanese pts.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

PharmaMar.

Funding

Has not received any funding.

Disclosure

S. Takahashi: Honoraria (self): Daiichi Sankyo, Sanofi, Eisai, Bayer, Taiho Pharmaceutical, MSD, Novartis, Chugai Pharma, AstraZenca, Astellas Pharma, Bristol-Myers Squibb Japan, Ono Pharmaceutical, Kyowa Hakko Kirin, Nihonkayaku, Pfizer, Lilly Kapan; Advisory/Consultancy: Bayer; Research grant/Funding (self): Daiichi Sankyo, Sanofi, Eisai, Bayer, Taiho Pharmaceutical, MSD, Novartis, Chugai Pharma, AstraZenca, Bristol-Myers Squibb, Lilly, Ono Pharmaceutical, PharmaMar, Pfizer/EMD Serono; Travel/Accommodation/Expenses: Daiichi Sankyo, Novartis. T. Shimizu: Honoraria (self): Daiichi Sankyo, Boehringer; Advisory/Consultancy: Takeda Oncology; Research grant/Funding (self): Novartis, Eli Lilly, Daiichi Sankyo, Bristol-Myers Squibb, Symbio Pharmaceuticals, Takeda, 3D-Medicine, AstraZeneca, Eisai, AbbVie, Incyte, Astellas Pharma, Chordia Therapeutics, Five Prime, PharmaMar; Travel/Accommodation/Expenses: Eisai, Takeda Oncology. T. Doi: Advisory/Consultancy: Lilly Japan, Chigai Pharma, Kyowa Hakko Kirin, MSD, Daiichi Sankyo, Amgen, Sumitomo Dianippon, Taiho Pharmaceutical; Research grant/Funding (self): Taiho Pharmaceutical, Novartis, Merck Serono, Astellas Pharma, MSD, Janssen, Boehringer Ingelheim, Takeda, Pfizer, Lilly Japan, Sumitomo Group, Chugai Pharma, Kyowa Hakko Kirn, Daiichi Sankyo, Celgene, Bristol-Myers Squibb, AbbVie, Quintiles. J.A. Lopez-Vilarino: Honoraria (self), Shareholder/Stockholder/Stock options: PharmaMar. R. Nunez Martin: Honoraria (self): PharmaMar. C. Kahatt: Honoraria (self), Shareholder/Stockholder/Stock options: PharmaMar. C. Fernandez Teruel: Shareholder/Stockholder/Stock options: PharmaMar. A. Zeaiter: Honoraria (self), Shareholder/Stockholder/Stock options: PharmaMar. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.